HQ Team
March 17, 2023: Jubilant HollisterStier, a subsidiary of India’s Jubilant Pharmova, has got Canada’s nod for a partially repayable loan of CAD 23.8 million ($17.7 million) for expansion in Montreal.
Canadian government’s Strategic Innovation Fund has agreed partially to fund the CAD 108 million expansion at the company’s manufacturing facility in the largest city in Quebec province.
The loan is in addition to earlier announced CAD 25 million loans committed by the Province of Quebec for the same expansion project.
The project aims to upgrade the company’s facility and increase its “fill and finish” capacity by over 100%, according to a BSE filing.
“This expansion project of the more than 40,000 square feet facility will result in world-class sterile manufacturing site, offering a wide range of fill and finish capabilities with flexibility in dose forms and batch sizes,” according to the statement.
Vial filling
The technology and equipment will comprise high-speed vial filling with an isolator barrier system, freeze drying, and a flex line capable of handling syringes, vials, and cartridges.
“Jubilant HollisterStier is excited to be chosen as a part of the eco-system being strengthened by Canada to better position the country for its future needs of vaccines and treatments for potential pandemics,” said Pramod Yadav, CEO of Jubilant Pharma.
Chris Preti, President of Contract Manufacturing Organization (CMO), Jubilant HollisterStier, said the expansion would target large pharmaceuticals and biotech companies’ parenteral products and feature a flexible manufacturing platform.
The platform will be able to produce multiple forms of vaccines, addressing a variety of future health emergencies, Mr Preti said.
Radiopharmacies
Jubilant HollisterStier LLC is a subsidiary of Jubilant Pharma Limited, a global integrated pharmaceutical company.
Jubilant Pharma operates in three segments speciality pharmaceuticals, contract manufacturing and generic.
The speciality pharmaceuticals comprise radiopharmaceuticals (including radiopharmacies) and allergy therapy products.
The company’s ‘CDMO’ segment consists of parenteral contract manufacturing and active pharmaceutical ingredients, and the generics segment is for the finished dosage formulations business.
The Noida, India-based company supplies its products and services to customers in over 85 countries and has four manufacturing facilities in North America and two in India.
It has a distribution network of more than 45 radiopharmacies in the US.
